Expression of mhc class i on breast cancer cells correlates inversely with her2 expression

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1104-1110

  Inoue, Masayuki ^a   Mimura, Kousaku ^a,b   Izawa, Shinichiro ^a   Shiraishi, Kensuke ^a   Inoue, Ayako ^a   Shiba, Shugo ^a   Watanabe, Mitsuaki ^a   Maruyama, Takanori ^a   Kawaguchi, Yoshihiko ^a   Inoue, Shingo ^a   Kawasaki, Tomonori ^a   Choudhury, Aniruddha ^c   Katoh, Ryohei ^a   Fujii, Hideki ^a   Kiessling, Rolf ^d   Kono, Koji ^a,b,e  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; CTL; HER2; MHC Class I; Ras MAPK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROGESTERONE RECEPTOR; RAS PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CORRELATION ANALYSIS; DOWN REGULATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84875191933     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21056     Document Type: Article

References (31)

1. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230:1132-9; PMID:2999974; http://dx.doi.org/10.1126/science. 2999974.
2. Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Störkel S, et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 2000; 87:349-59; PMID:10897039.
3. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92:1253-60; PMID:15785739;http://dx.doi.org/10.1038/ sj.bjc.6602499
4. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60:768-72; PMID:16882699; http://dx.doi.org/10.1136/jcp.2006.038281.
5. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98:833-7; PMID:11948459.
6. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-17; PMID:7539040; http:// dx.doi.org/10.1084/jem.181.6.2109.
7. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78:202-8; PMID:9754653.
8. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/ neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/ JCO.2008.20.6789.
9. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23:7536-45; PMID:16157940; http://dx.doi. org/10.1200/JCO.2005.03.047.
10. Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, et al. The impact of HER2/ neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15:2895-904; PMID:19351776; http://dx.doi. org/10.1158/1078-0432.CCR-08-1126.
11. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: USMilitary Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14:797-803; PMID:18245541; http://dx.doi. org/10.1158/1078-0432.CCR-07-1448.
12. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, et al. HER-2/neu-mediated regulation of components of the MHC class I antigenprocessing pathway. Cancer Res 2004; 64:215-20; PMID:14729627; http://dx.doi.org/10.1158/0008-5472.CAN-2522-2.
13. Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, et al. Down-regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 1998; 77:937-41; PMID:9714068.
14. Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunol Immunother 2006; 55:653-62; PMID:16151808; http://dx.doi. org/10.1007/s00262-005-0050-5.
15. Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 2011; 128:390-401; PMID:20715101; http://dx.doi.org/10.1002/ ijc.25613.
16. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58:903-13; PMID:14967450; http://dx.doi.org/10.1016/j.ijrobp.2003.06.002.
17. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108:71-7; PMID:14618618; http://dx.doi. org/10.1002/ijc.11497.
18. DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004; 15:1510-6; PMID:15367412; http:// dx.doi.org/10.1093/annonc/mdh388.
19. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27; PMID:15324695; http://dx.doi. org/10.1016/j.ccr.2004.06.022.
20. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57:237-43; PMID:10617300; http://dx.doi. org/10.1023/A:1006273516976.
21. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol-3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-24; PMID:11139588; http://dx.doi.org/10.1074/jbc. M010840200.
22. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008; 57:1511-21; PMID:18536917; http://dx.doi.org/10.1007/s00262-008-0540-3.
23. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptidespecific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58:4902-8; PMID:9809997.
24. Conrad H, Gebhard K, Krönig H, Neudorfer J, Busch DH, Peschel C, et al. CTLs directed against HER2 specifically cross-react with HER3 and HER4. J Immunol 2008; 180:8135-45; PMID:18523278.
25. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008; 99:1462-7; PMID:18841157; http://dx.doi.org/10.1038/ sj.bjc.6604715.
26. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57:1719-26; PMID:18408926; http://dx.doi.org/10.1007/s00262-008-0515-4.
27. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, et al. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 2010; 103:552-9; PMID:20628381; http://dx.doi.org/10.1038/ sj.bjc.6605772.
28. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010; 8:53; PMID:20529245; http://dx.doi. org/10.1186/1479-5876-8-53.
29. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010; 16:1486-97; PMID:20179226; http://dx.doi.org/10.1158/1078-0432.CCR-09-1764.
30. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996; 73:1233-6; PMID:8630284; http:// dx.doi.org/10.1038/bjc.1996.236.
31. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; PMID:19436038; 101:736-50; http:// dx.doi.org/10.1093/jnci/djp082.